A Hyderabad-based vaccine company today announced that it received regulatory approval to launch a Phase III clinical trial for a COVID-19 vaccine candidate.
Biological E. Limited (BE) confirmed on April 23, 2021, its subunit COVID-19 vaccine candidate includes an antigen developed by Texas Children’s Hospital Center for Vaccine Development and in-licensed from Baylor College of Medicine’s integrated commercialization team along with Dynavax Technologies Corporation’s advanced adjuvant CpG 1018TM.
India Authorizes Phase Three Study for Subunit COVID-19 Vaccine Candidate
Millions of Americans Have Missed Their Second COVID-19 Vaccine Dose: CDC
Local health authorities struggling to make sure that those who get their first shot also get their second
Lower Incomes Increase Cancer Worry, Anxiety During Pandemic
Worry, anxiety up with lower annual income for Medicaid-insured women receiving gynecologic oncology care during March 15 to April 15, 2020
CDC Issues Updated Summer Camp Guidelines
When activities must be indoors, spaces should be well ventilated and windows should be kept open
COVID-19 Vaccinations Now Mandatory for Houston Methodist Hospital Workers
In March, health system gave vaccinated workers an extra $500 and warned that at some point the shots would no longer be voluntary
EU Will Allow Fully Vaccinated U.S. Tourists
No word on a timeline on when exactly tourist travel might open up or details on how it would occur
U.S. Will Help India in Fight Against COVID-19: Biden
United States is ‘working around the clock’ to immediately send drug treatments and rapid diagnostic COVID-19 testing kits to India